# Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer

Source: https://onco.cc/trials/nct04768426/  
OnCo record `nct04768426` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of capecitabine in triple-negative breast cancer, run by Stanford University, now recruiting.

## Summary

Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer is a phase 2, interventional study registered as NCT04768426 by Stanford University, with a registry enrolment figure of 40 participants, started 2021-02-03 and due to reach its primary completion in 2026-11. Interventions recorded: Capecitabine. Conditions listed: Triple Negative Breast Cancer; Breast Cancer. Triple-negative eligibility wording from the registry: "Anatomic stage I - III triple-negative breast cancer at diagnosis". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT04768426
- Phase: 2
- Setting: Phase II Trial of Circulating Tumor DNA Monitoring During Adjuvant Capecitabine in Patients With Triple-negative Breast Cancer and Residual Disease Following Standard Neoadjuvant Chemotherapy
- Sponsor: Stanford University
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT04768426: https://clinicaltrials.gov/study/NCT04768426

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct04768426.json